| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Physics, National Taiwan Normal University, Taipei, Taiwan
Correspondence: Address reprint requests to C.-M. Chen, E-mail: cchen{at}phy.ntnu.edu.tw.
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The role of PrPSc in the pathologic mechanism of prion diseases is currently unknown. Recent experiments have observed that PrPSc deposition fails to cause disease in brain tissue lacking PrPc and that the time course of PrPSc deposition in the brains of mice expressing low levels of PrPc does not correlate with the time course of neurodegeneration (6
,7
). Conversely, it is also observed that substantial neurodegeneration could occur in the absence of PrPSc accumulation in several prion diseases (8
12
). These observations suggest that PrPSc is not directly toxic and its accumulation is not the only cause of pathology in prion diseases.
Studies of PrP translocation at the endoplasmic reticulum (ER) membrane have found three topologic forms of PrP, including one cell-surface form (secPrP) and two transmembrane (TM) forms (CtmPrP and NtmPrP) (13
15
). Several pieces of evidence have implied the importance of CtmPrP in the pathogenesis of prion diseases. It is found that transgenic mice overexpressing CtmPrP develop a spontaneous neurological disease with scrapie-like features, in the absence of PrPSc. In addition, patients affected by Gerstmann-Straussler-Scheinker disease associated to an A117V mutation exhibit an increased production of this TM form of PrP, suggesting that the basis of this disease lies in increased production of CtmPrP (16
,17
). These findings suggest that CtmPrP may have important implications for a broad range of neurodegenerative diseases. Nevertheless, not much is known about the pathological mechanism so far.
Numerous computational studies have provided valuable information about the structure and mechanism of formation of amyloids by using various modeling techniques and various levels of protein representation (18
22
). Simulations at the atomic resolution can study relative stability and flexibility of the native structure of prions, their amyloidlike model structure, and possible intermediate structures during aggregation (19
,20
). However, it would be computationally too demanding to investigate protein refolding and aggregation. On the other hand, idealized simple lattice models have shown that prion aggregation can lead to significant change of the single chain conformation (21
). Moreover, simulations at protein level can provide a bridge between the short distance and timescales covered in individual protein models and the long time, macroscopic realm of chemical kinetics (22
).
In this work, we propose a model for the contact-induced structure transformation of the transmembrane domain of CtmPrP, which is studied by Monte Carlo simulations using a coarse-grained protein model. In this model, the transmembrane domain can fold into a well-defined helical "native conformation" (Fig. 1 a) and also assume a metastable ß-type structure (Fig. 1 b). For a protein monomer, the helical structure corresponds to the global energy minimum and the metastable structure to a higher-energy local minimum of the energy landscape. For a system of more than one chain, the ground state structure of the energy landscape is a linear crystal consisting of ß-form chains. Similar mechanisms have been previously proposed for a prionlike propagation in solution using a lattice model (23
,24
) or an off-lattice reduced protein model (20
), whose purpose is to mimic the observed amyloid aggregation in solution with certain artificially designed amino-acid sequences. In this article, we investigate the problem of prion propagation for the transmembrane domain of CtmPrP, which infers a new perspective of the pathological mechanism of prion diseases as suggested by recent experiments (13
17
). We speculate that the amyloid aggregation in the membrane could lead to rupture of membrane and cause the death of nerve cells. This model is used to investigate the correlation between concentration and the average refolding time of a helical form to a ß-form, in the presence of a ß-form template. We find that cooperativity plays an important role in the contact-induced structure transformation. In this case, an excellent agreement with experimental data for transgenic mice is found in the calculated correlation between folding time and prion concentration (25
).
|
| MODEL |
|---|
|
|
|---|

i,j
|(ni · rij) (nj · rij)|
r(i,j),4, where ni is the N-H (or O=C) bond orientation of the ith amino acid, while r(i,j) and rij are the distance and its unit vector between amino acids i and j. Since the backbone hydrogen bonding is the dominant interaction for the formation of secondary structures of MPs, its energy strength is set to unity. Furthermore we have explicitly excluded the possibility of forming 27 ribbons and 310 helices due to steric hindering by disallowing the hydrogen bonding between (i, i±2) and (i, i±3) pairs. The bending energy of the chain is assumed to be e1
i (1cos
i), where e1 is the bending rigidity and
i is the angle between two consecutive bonds i and i+1. For amino acids in water, their interactions are modeled by a residue-residue contact potential (Econtact) and the hydropathical interaction (Ehydropathy), i.e., Uwater = Econtact + Ehydropathy. The interactions between the exposed residues and the lipid bilayer are ignored. Here we use the Thomas-Dill contact potential with strength e2 to model the residue-residue interaction in water when residues are in contact (27
Algorithm of simulations
Protein is represented as a chain of monomers in lattice space using the bond fluctuation model (31
). Each monomer in the model is a cube of length 1 (lattice spacing) on a cubic lattice. The set of allowed bond vectors is B = P(2,0,0)
P(2,1,0)
P(2,1,1)
P(2,2,1)
P(3,0,0)
P(3,1,0), where P(a,b,c) stands for the set of all permutations and sign combinations of ±a, ±b, ±c. The number of configurations per bond is z = 108. The length of one bond can take any one of the five values: 2, 51/2, 61/2, 3, or 101/2 (in units of lattice spacing). Chains satisfy the excluded volume constraint: no lattice site may be occupied by more than one monomer. The set B is chosen to satisfy the constraints of both excluded volume between monomers and topological entanglement between chains (i.e., two chains cannot pass through each other). If any other bond vectors were added to this set, some chains would become "phantom" chains. The folding of a protein chain is simulated by the Metropolis Monte Carlo (MC) algorithm in a cubic lattice at a constant temperature T. At each instant, a residue is picked up at random and attempts to move in any of the six directions by one lattice spacing. If any attempted move of residues satisfies the excluded volume constraint and the new bond vectors are still in the allowed set, then the move is accepted with probability p = min[1, exp(
H/T)], where
H is the enthalpy change of the system. Each physical quantity calculated in the present work is averaged over 100 different runs.
| RESULTS AND DISCUSSION |
|---|
|
|
|---|
30 residues shows that ShaPrP contains a stable TM domain stretching from H111 to V135, which has the largest accumulated hydropathy index (
) for various values of WS. Similar TM domain (stretching from M112 to V135) is predicted if the Hoop-Woods index is replaced by the Kyte-Doolittle index, as shown in Fig. 3. In our model, the native conformation of this TM domain corresponds to the structure of a simple
-helical motif (Fig. 1 a), whereas the metastable structure adopted a ß-motif (Fig. 1 b). The conformational energies of these structures are 13.9 and 8, respectively. With low-temperature range (T = 0.10.15) and the ß-form as the initial configuration, the protein remains in the ß-form for simulations of 106 MC steps, confirming its metastable character. Fig. 4 shows the temperature dependence of helical fraction and the mean first passage time (MFPT) to the helical state (ground state), starting from a random initial configuration. The optimal folding temperature for our model is 0.31 (the corresponding thermal energy is
3 kJ/mol). The average helical fraction of the chain is calculated during a period of 103 MC steps for 10 different simulations at each temperature, after the chain has been simulated for 105 MC steps. The large values of helical fraction of the chain at various temperatures imply that there is a large basin associated with the helical state in the configuration space.
|
|
|
-helical motif, which is free to diffuse in the membrane. The
-helical form first unfolds and then refolds to the ß-form in the presence of the template, assembling into a larger ß-type dimer structure (Fig. 5). Due to the favorable intermolecule hydrogen bonding interaction, the energy of the dimer (28) is lower than twice of the single-helical molecule (27.8). If we use a random initial configuration for the second protein, it will quickly fold into the ß-form due to its contact with the template. Such a dimer structure is stable for simulations longer than 106 MC steps at the optimal folding temperature, in which case both proteins are free to move. Nevertheless, the formation of the ß-type dimer has never been observed in our simulations (longer than 107 MC steps) for systems starting from two unfolded or helical structures, which implies that a spontaneous transition from the native to the propagating scrapie form of the TM domain must be a rare event in our model. In this model, the hairpin structure is kinetically unfavorable due to the fact that hydrogen bonding is a local interaction for the helical state but is a nonlocal interaction for the hairpin state. As shown in Chen (30
|
|
|
h) in the moving probability of this residue to enhance the cooperative hairpin formation (without violating the detail balance), where
h is the change in the number of hydrogen-bonding pairs consistent with hydrogen-bonding pairs in the template and ß is the cooperative factor (26
|
|
| CONCLUSION |
|---|
|
|
|---|
| ACKNOWLEDGEMENTS |
|---|
|
|
|---|
Submitted on September 28, 2006; accepted for publication January 9, 2007.
| REFERENCES |
|---|
|
|
|---|
2. Weissmann, C. 1999. Molecular genetics of transmissible spongiform encephalopathies. J. Biol. Chem. 274:36.
3. Johnson, R. T., and C. J. Gibbs. 1998. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N. Engl. J. Med. 399:19942004.
4. Horwich, A. L., and J. S. Weissman. 1997. Deadly conformationsprotein misfolding in prion disease. Cell. 89:499510.[CrossRef][Medline]
5. Weissmann, C. 2004. The state of the prion. Nat. Rev. Microbiol. 2:861871.[CrossRef][Medline]
6. Manson, J. C., A. R. Clarke, P. A. McBride, I. McConnell, and J. Hope. 1994. PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. J. Neurodeg. 3:331340.
7. Bûeler, H., A. Raeber, A. Sailer, M. Fischer, A. Aguzzi, and C. Weissmann. 1994. High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol. Med. 1:1930.[Medline]
8. Tateishi, J., K. Koh-ura, T. Kitamoto, C. Tranchant, G. Steinmetz, J. M. Warter, and J. W. Boellaard. 1992. Prion protein gene analysis and transmission studies of Creutzfeldt-Jakob disease. In Prion Diseases of Humans and Animals. S. B. Prusiner, J. Collinge, J. Powell, and B. Anderton, editors. Horwood, London.
9. Collinge, J., M. S. Palmer, K. C. Sidle, I. Gowland, R. Medori, J. Ironside, and P. Lantos. 1995. Transmission of fatal familial insomnia to laboratory animals. Lancet. 346:569570.[CrossRef][Medline]
10. Tateishi, J., P. Brown, T. Kitamoto, Z. M. Hoque, R. Roos, R. Wollman, L. Cervenakova, and D. C. Gajdusek. 1995. First experimental transmission of fatal familial insomnia. Nature. 376:434435.[CrossRef][Medline]
11. Hayward, P. A., J. E. Bell, and J. W. Ironside. 1994. Prion protein immunocytochemistry: reliable protocols for the investigation of Creutzfeldt-Jakob disease. Neuropathol. Appl. Neurobiol. 20:375383.[Medline]
12. Hsiao, K. K., D. Groth, M. Scott, S.-L. Yang, H. Serban, D. Rapp, D. Foster, M. Torchia, S. J. DeArmond, and S. B. Prusiner. 1994. Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein. Proc. Natl. Acad. Sci. USA. 91:91269130.
13. Hay, B., R. A. Barry, I. Lieberburg, S. B. Prusiner, and V. R. Lingappa. 1987. Biogenesis and transmembrane orientation of the cellular isoform of the scrapie prion protein. Mol. Cell. Biol. 7:914920.
14. Yost, C. S., C. D. Lopez, S. B. Prusiner, R. M. Myers, and V. R. Lingappa. 1990. Non-hydrophobic extracytoplasmic determinant of stop transfer in the prion protein. Nature. 343:669672.[CrossRef][Medline]
15. Lopez, C. D., C. S. Yost, S. B. Prusiner, R. M. Myers, and V. R. Lingappa. 1990. Unusual topogenic sequence directs prion protein biogenesis. Science. 248:226229.
16. Hegde, R. S., J. A. Mastrianni, M. R. Scott, K. A. DeFea, P. Tremblay, M. Torchia, S. J. DeArmond, S. B. Prusiner, and V. R. Lingappa. 1998. A transmembrane form of the prion protein in neurodegenerative disease. Science. 279:827834.
17. Hegde, R. S., P. Tremblay, D. Groth, S. J. DeArmond, S. B. Prusiner, and V. R. Lingappa. 1999. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature. 402:822826.[CrossRef][Medline]
18. Thirumalai, D., D. K. Klimov, and R. I. Dima. 2003. Emerging ideas on the molecular basis of protein and peptide aggregation. Curr. Opin. Struct. Biol. 13:146159.[CrossRef][Medline]
19. Armen, R. S., M. L. DeMarco, D. O. V. Alonso, and V. Daggett. 2004. Pauling and Corey's
-pleated sheet structure may define the prefibrillar amyloidogenic intermediate in amyloid disease. Proc. Natl. Acad. Sci. USA. 101:1162211627.
20. Malolepsza, E., M. Boniecki, A. Kolinski, and L. Piela. 2005. Theoretical model of prion propagation: a misfolded protein induces misfolding. Proc. Natl. Acad. Sci. USA. 102:78357840.
21. Harrison, P. M., H. S. Chan, S. B. Prusiner, and F. E. Cohen. 2001. Conformational propagation with prion-like characteristics in a simple model of protein folding. Protein Sci. 10:819835.
22. Slepoy, A., R. R. P. Singh, F. Pázmándi, R. V. Kulkarni, and D. L. Cox. 2001. Statistical mechanics of prion diseases. Phys. Rev. Lett. 87:058101.[CrossRef][Medline]
23. Harrison, P. M., H. S. Chan, S. B. Prusiner, and F. E. Cohen. 1999. Thermodynamics of model prions and its implications for the problem of prion protein folding. J. Mol. Biol. 286:593606.[CrossRef][Medline]
24. Dima, R. I., and D. Thirumalai. 2002. Exploring protein aggregation and self-propagation using lattice models: Phase diagram and kinetics. Protein Sci. 11:10361049.
25. Prusiner, S. B., P. Tremblay, J. Safar, M. Torchia, and S. J. DeArmond. 1999. Bioassays of Prions. In Prion Biology and Diseases. S. B. Prusiner, editor. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
26. Chen, C.-M., and C.-C. Chen. 2003. Computer simulations of membrane protein folding: structure and dynamics. Biophys. J. 84:19021908.
27. Thomas, P. D., and K. A. Dill. 1996. An iterative method for extracting energy-like quantities from protein structures. Proc. Natl. Acad. Sci. USA. 93:1162811633.
28. Hopp, T., and K. Woods. 1981. Prediction of protein antigenic determinants from amino acid sequences. Proc. Natl. Acad. Sci. USA. 78:38243828.
29. White, S. H., and W. C. Wimley. 1999. Membrane protein folding and stability: physical principles. Annu. Rev. Biophys. Biomol. Struct. 28:319365.[CrossRef][Medline]
30. Chen, C.-M. 2001. Lattice model of transmembrane polypeptide folding. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 63:010901.
31. Chen, C.-M., and P. G. Higgs. 1998. Monte-Carlo simulations of polymer crystallization in dilute solution. J. Chem. Phys. 108:43054314.[CrossRef]
32. Tompa, P., G. E. Tusnady, P. Friedrich, and I. Simon. 2002. The role of dimerization in prion replication. Biophys. J. 82:17111718.
33. Hardy, J., and D. J. Selkoe. 2002. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science. 297:353356.
34. Kayed, R., E. Head, J. L. Thompson, T. M. McIntire, S. C. Milton, C. W. Cotman, and C. G. Glabe. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 300:486489.
35. Kimberlin, R. H., and C. A. Walker. 1988. Pathogenesis of experimental scrapie. In Novel Infectious Agents and the Central Nervous System. T. Bock and J. Marsh, editors. CIBA Foundation Symposium, Wiley, Chichester.
36. Manuelidis, L., and W. Fritch. 1996. Infectivity and host responses in Creutzfeldt-Jakob disease. Virology. 216:4659.[CrossRef][Medline]
37. Kulkarni, R. V., A. Slepoy, R. R. P. Singh, D. L. Cox, and F. Pázmándi. 2003. Theoretical modeling of prion disease incubation. Biophys. J. 85:707718.
38. Russell, S. J., T. Blandl, N. J. Skelton, and A. G. Cochran. 2003. Stability of cyclic ß-hairpins: asymmetric contributions from side chains of a hydrogen-bonded cross-strand residue pair. J. Am. Chem. Soc. 125:388395.[CrossRef][Medline]
39. Sharman, G. J., and M. S. Searle. 1998. Cooperative interaction between the three strands of a designed antiparallel ß-sheet. J. Am. Chem. Soc. 120:52915300.
40. Schenck, H. L., and S. H. Gellman. 1998. Use of a designed triple-stranded antiparallel ß-sheet to probe ß-sheet cooperativity in aqueous solution. J. Am. Chem. Soc. 120:48694870.[CrossRef]
41. Baumgartner, A. 1996. Insertion and hairpin formation of membrane proteins: a Monte Carlo study. Biophys. J. 71:12481255.
42. Cantor, R. S. 1999. Solute modulation of conformational equilibria in intrinsic membrane proteins: apparent "cooperativity" without binding. Biophys. J. 77:26432647.
43. Mclean, A. R., and C. J. Bostock. 2000. Scrapie infections initiated at varying doses: an analysis of 117 titration experiments. Philos. Trans. R. Soc. Lond. B Biol. Sci. 355:10431050.[CrossRef][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |